AMPERSAND BIOMEDICINES
Ampersand Biomedicines is an Address, Navigate, Design (AND)™ Platform that develops novel programming therapeutics that are designed to act at the sight of disease.
AMPERSAND BIOMEDICINES
Industry:
Biopharma Biotechnology Medical Therapeutics
Founded:
2020-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.ampersand.bio
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
50 M USD
Technology used in webpage:
Domain Not Resolving Google Maps CrUX Dataset CrUX Top 10m Amazon Elastic Load Balancing Amazon ELB North Virginia
Similar Organizations
Achelois BioPharma
Achelois develops programmable therapeutics for cancer, viral infections, autoimmune, and inflammatory diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-01-03 | AbCheck | AbCheck acquired by Ampersand Biomedicines | 6 M USD |
Investors List
Flagship Pioneering
Flagship Pioneering investment in Venture Round - Ampersand Biomedicines
Official Site Inspections
http://www.ampersand.bio Semrush global rank: 6.08 M Semrush visits lastest month: 1.13 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Ampersand Biomedicines"
Ampersand Biomedicines - Crunchbase Company …
Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely. Utilizing a computational platform, Ampersand identifies ideal drug localization strategies, informing the design of …See details»
Leadership - Ampersand Biosciences
Ampersand is the second company she has started: In 2005, she launched Multiplex Biosciences to offer custom multiplex services. That company was acquired by Rules Based Medicine …See details»
Forging Leaders in Healthcare & Life Sciences
Ampersand is dedicated to Forging Leaders in Healthcare & Life Sciences.We focus on empowering our portfolio companies and partnering closely with founders and leadership teams to build value together.. By maintaining their …See details»
Ampersand Biomedicines - The Org
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art …See details»
Avid Bioservices to be Acquired by GHO Capital Partners and …
TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract …See details»
Team - Ampersand
Raffi is a Co-Founder and the Chief Innovation Officer at Ampersand Biomedicines, as well as a Senior Principal at Flagship Pioneering. He joined Flagship in 2021 and works as part of a team exploring innovative ideas to …See details»
Home | Ampersand Biosciences
Ampersand Bio is a two time winner for the SBIR grant and has been published or cited in many academic papers. More About Our Research Ampersand Biosciences was the recipient of the SBIR award in 2020, 2022, 2024 for …See details»
GHO & Ampersand Complete Acquisition of Avid Bioservices
Feb 5, 2025 On 7 November 2024, GHO and Ampersand entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and Ampersand in an all-cash …See details»
Flagship’s Ampersand Bio Adds $65M to Solve One of the Top …
Mar 19, 2025 Ampersand bolstered its technology with the 2024 acquisition of AbCheck, a company that brought new antibody discovery capabilities. Gardner, who is also a CEO …See details»
Ampersand - Ampersand Biomedicines Acquires AbCheck to …
BOSTON, Mass., January 3, 2024 – Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, …See details»
Ampersand Biomedicines - Leadership Team - The Org
The Leadership Team at Ampersand Biomedicines is responsible for setting the strategic direction and overseeing the implementation of the company's innovative approach to programmable …See details»
On the heels of raising a $65M series B, the CEO of Flagship's ...
Apr 3, 2025 Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. …See details»
About - Ampersand Biosciences
Ampersand Biosciences offers one of a kind Luminex products for Ferret and Hamster cytokine panels specifically developed to evaluate respiratory diseases. Our Ferret Cytokine Panel 2 …See details»
Ampersand - Flagship Pioneering Unveils Ampersand …
Mar 7, 2023 Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. For more information, please visit www.ampersand.bio. About Flagship …See details»
Newsroom | Ampersand Biosciences
Sep 30, 2024 Ampersand Biosciences was awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) on July 1, 2020 until August 31, 2022 to address an …See details»
Platform - Ampersand
The Address Map is based on a comprehensive multi-omics characterization of human biology, spanning healthy and diseased states. The platform is trained to explore an unprecedented …See details»
Ampersand - Ampersand Biomedicines Raises Series B Financing …
BOSTON, March 19, 2025 – Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, …See details»
Grants & Research - Ampersand Biosciences
This ongoing SBIR grant, awarded in 2022 to Ampersand Biosciences and principal investigator Tori Race, seeks to produce and test monoclonal antibodies against 10 cytokines and …See details»
Flagship Pioneering Announces Two New Agreements with …
CAMBRIDGE, Mass., November 20, 2024 – Flagship Pioneering, the bioplatform innovation company today announced Ampersand Biomedicines and Montai Therapeutics have entered …See details»
BIO Elects Genentech’s Fritz Bittenbender as New Board Chair
1 day ago Industry veteran takes the helm as Dr. Ted Love concludes two-year term marked by strategic growth and transition . BOSTON (June 16, 2025) – Today, the Biotechnology …See details»